The autologous CAR T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated effectiveness and safety consistent with the ZUMA-5 trial when used in real-world settings to treat a broader population of patients with follicular lymphoma (FL).
In the largest report of real-world axicabtagene ciloleucel (axi-cel) outcomes among patients with relapsed or refractory follicular lymphoma (R/R FL), including patients who would have been ineligible for the pivotal ZUMA-5 trial, the chimeric antigen receptor (CAR) T-cell therapy showed safety and efficacy consistent with trial outcomes.1 The findings were presented during a poster discussion session at the 2023 American Society of Clinical Oncology Annual Meeting.
In the pivotal ZUMA-5 trial of axi-cel in R/R FL following at least 2 lines of therapy, the primary analysis showed a 94% objective response rate (ORR) and a 79% complete response (CR) rate in patients treated with axi-cel.2 Regarding safety, cytokine release syndrome (CRS) grade 3 or higher occurred in 6% of patients, and neurologic events occurred in 15% of patients.
In the new analysis, the patient population is significantly broader than that of the ZUMA-5 trial. Of 230 patients in the real-world study population, 40% would have been excluded from the ZUMA-5 trial, mainly due to comorbidities.
The median patient age was 62 years, and 60% of patients in the study were male. Patients had a median of 4 lines of therapy prior to receiving axi-cel, 14% had undergone prior autologous stem cell transplantation, and 9% received bridging therapy. Patients who received previous nontransplant cellular therapy, including prior CAR T-cell therapy, were excluded.
Among 151 patients with follow-up data at a median of 6.2 months, the ORR was 93% (95% CI, 88% to 97%) and the CR rate was 84% (95% CI, 77% to 89%). The estimated progression-free survival (PFS) and overall survival (OS) were 88% (95% CI, 81% to 92%) and 96% (95% CI, 91% to 98%).
“Despite a broader patient population and relatively limited follow-up in the real world, early results demonstrate favorable effectiveness and safety outcomes with axi-cel in patients with relapsed or refractory follicular lymphoma that are consistent with those observed in the pivotal ZUMA-5 trial, supporting postauthorization use of this CAR T-cell therapy in this setting,” said lead study author and presenter Caron A. Jacobson, MD, MMSc, medical director of the Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School.
CRS considered grade 3 or higher by ASTCT consensus occurred in 2% of patients (95% CI, 0% to 6%), and immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 13% of patients (95% CI, 8% to 19%). The median cumulative incidence estimates of CRS and ICAN resolution were 5 days and 4 days, respectively. Among 150 patients who were alive at day 30, prolonged cytopenia occurred in 11%.
Notably, PFS and OS at 6 months post-treatment were similar regardless of patient eligibility by ZUMA-5 trial criteria. However, those who would have been eligible for ZUMA-5 showed lower rates of grade 3 or higher ICANS and quicker ICANS resolution.
References
1. Jacobsen CA, Hemmer MT, Hu ZH, et al. Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL). J Clin Oncol. 2023;41(suppl 16):7509. doi:10.1200/JCO.2023.41.16_suppl.7509
2. Jacobsen CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91-103. doi:10.1016/S1470-2045(21)00591-X
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More